PARP-1-IN-3 Secrets
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo goals were being to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis